仑伐替尼联合抗PD-1治疗晚期甲状腺癌的可诱导转基因模型耐药机制研究
该研究在TPO-CreER/BrafV600E/wt/Trp53Δex2-10/Δex2-10可诱导转基因晚期甲状腺癌小鼠模型中,诱导后3.5个月肿瘤建立后给予高剂量(10 mg/kg)或低剂量(2 mg/kg)仑伐替尼、抗PD-1或联合治疗。结果显示低剂量和高剂量仑伐替尼均缩小肿瘤体积,抗PD-1单用或联用均无效;低剂量仑伐替尼对肿瘤大小控制更优,但肺转移和生存未改善。低剂量仑伐替尼轻微减少Ly6G+CD11b+髓系细胞,增加CD4+ T细胞浸润及4-1BB+、颗粒酶B+ CD4+ T细胞和FoxP3+调节性T细胞富集,多数小鼠出现多克隆T细胞扩增。
要点
- 低剂量仑伐替尼在控制原发肿瘤体积上优于高剂量,但均未改善肺转移或生存。
- 抗PD-1单用或联合仑伐替尼在该模型中均未显示疗效。
- 低剂量仑伐替尼可调节免疫微环境并诱导多克隆T细胞扩增,但不足以持久消退肿瘤。
核心结论
- 仑伐替尼对免疫应答的影响在低剂量治疗组最明显,提示临床应用中应考虑剂量选择。
- 仑伐替尼的免疫调节潜力令人鼓舞,但免疫微环境和T细胞活化状态的改变不足以维持持久肿瘤消退,即使联合抗PD-1。
- 需要进一步研究为低突变负荷肿瘤(如甲状腺癌)开发更有效的联合方案。
研究设计与样本
- 研究采用TPO-CreER/BrafV600E/wt/Trp53Δex2-10/Δex2-10可诱导转基因晚期甲状腺癌小鼠模型。
- 诱导后3.5个月肿瘤建立,小鼠接受高剂量(10 mg/kg)或低剂量(2 mg/kg)仑伐替尼、抗PD-1或仑伐替尼联合抗PD-1治疗。
- 评估各组肿瘤体积和肺转移,通过流式细胞术和免疫组化表征免疫浸润,并进行TCRβ测序分析T细胞应答。
主要发现
- 低剂量和高剂量仑伐替尼均缩小肿瘤体积,而抗PD-1单用或联用均无效果。
- 低剂量和高剂量仑伐替尼均降低血管密度,但低剂量仑伐替尼在控制肿瘤大小方面更优。
- 尽管仑伐替尼影响原发肿瘤大小,但肺转移和生存未获改善。
- 低剂量仑伐替尼轻微减少优势Ly6G+CD11b+髓系细胞群,并伴随CD4+ T细胞浸润增加及4-1BB+和颗粒酶B+ CD4+ T细胞与FoxP3+调节性T细胞富集。
- 多数小鼠出现多克隆T细胞扩增,提示产生了肿瘤特异性T细胞应答。
临床怎么用
- 临床联合应用仑伐替尼与抗PD-1时需考虑仑伐替尼剂量对免疫调节效应的影响。
- 仑伐替尼单药或联合抗PD-1可能不足以在低突变负荷甲状腺癌中实现持久肿瘤消退。
局限性
- 研究为临床前小鼠模型,结果需在人体临床试验中验证。
- 模型中抗PD-1单用或联合仑伐替尼均未显示疗效,可能限制结论的外推。
- 免疫微环境改变与T细胞活化不足以维持持久肿瘤消退,具体耐药机制仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Combination therapy with lenvatinib plus programmed death-1 (PD-1) immune checkpoint blockades (ICBs) is under investigation in many solid tumors, including thyroid cancer. Lenvatinib is known to reduce angiogenesis and may overturn the immunosuppressive effects of vascular endothelial growth factor in the tumor microenvironment. Previous studies investigating the effects of VEGF receptor inhibition on the immune response were performed in rapidly growing tumor models where immune equilibrium is not established before treatment. We hypothesize that physiologically relevant preclinical models are necessary to define mechanisms of resistance to immune-targeted combination therapies. Methods: We utilized the TPO-CreER/BrafV600E/wt/Trp53Δex2-10/Δex2-10 inducible transgenic model of advanced thyroid cancer to investigate lenvatinib treatment in the context of an anti-PD-1 ICB. Following tumor establishment, 3.5 months postinduction, mice were treated with high- (10 mg/kg) or low-dose (2 mg/kg) lenvatinib, anti-PD-1, or combination of lenvatinib with anti-PD-1. Tumor volume and lung metastases were assessed in each group. Immune infiltrate was characterized by flow cytometry and immunohistochemistry, and TCRß sequencing was performed to further investigate the T cell response. Results: Both low- and high-dose lenvatinib reduced tumor volume, while anti-PD-1 had no effect, alone or in combination. Although both low- and high-dose lenvatinib reduced vascular density, low-dose lenvatinib was superior in controlling tumor size. Lung metastases and survival were not improved with therapy despite the effects of lenvatinib on primary tumor size. Low-dose lenvatinib treatment led to a subtle reduction in the dominant Ly6G+CD11b+ myeloid cell population and was associated with increased CD4+ T cell infiltrate and enrichment in 4-1BB+ and granzyme B+ CD4+ T cells and FoxP3+ regulatory T cells. Polyclonal T cell expansion was evident in the majority of mice, suggesting that a tumor-specific T cell response was generated. Conclusions: The effects of lenvatinib on the immune response were most pronounced in mice treated with low-dose lenvatinib, suggesting that dose should be considered in clinical application. While the immune-modulating potential of lenvatinib is encouraging, alterations in the immune milieu and T cell activation status were insufficient to sustain durable tumor regression, even with added anti-PD-1. Additional studies are necessary to develop more effective combination approaches in low-mutation burden tumors, such as thyroid cancer.
引用
- Bertol BC, Bales ES, Calhoun JD, et al. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022. PMID: 34641722. doi:10.1089/thy.2021.0371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。